(Q34466646)

2 August 2017

title

Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population (English)

1 reference

2 August 2017

1 reference

A Dang

1

1 reference

2 August 2017

Y Zhang

2

1 reference

2 August 2017

G Liu

3

1 reference

2 August 2017

G Chen

4

1 reference

2 August 2017

W Song

5

1 reference

2 August 2017

B Wang

6

1 reference

2 August 2017

publication date

1 January 2006

1 reference

Journal of Human Hypertension

2 August 2017

published in

1 reference

2 August 2017

volume

20

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

45-50

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.jhh.1001941

2 August 2017

exact match

0 references

cites work

Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001941

Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001941

Uric acid and diet--insights into the epidemic of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001941

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001941

Purine-rich foods, dairy and protein intake, and the risk of gout in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001941

Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001941

Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001941

Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001941

Uric acid as a cardiovascular risk factor in arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001941

7 January 2021

Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001941

7 January 2021

Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001941

7 January 2021

Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001941

7 January 2021

Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001941

7 January 2021

Identifiers

DOI

10.1038/SJ.JHH.1001941

1 reference

Dimensions Publication ID

2 August 2017

1009561951

0 references

1 reference